Inactive Instrument

Cesca Therapeutics Inc Stock Nasdaq

Equities

US1571311034

Office Equipment

Sales 2024 * 16.86M Sales 2025 * 21.11M Capitalization 5.17M
Net income 2024 * 2M Net income 2025 * 5M EV / Sales 2024 * 0.31 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.24 x
P/E ratio 2024 *
8.13 x
P/E ratio 2025 *
3.25 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.89%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 53 16-03-09
Director of Finance/CFO 51 09-12-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 69 17-02-23
Director/Board Member 78 17-01-09
Chief Executive Officer 53 16-03-09
More insiders
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. It provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and the CAR-TXpress platform for large scale cell manufacturing services. Its products include Clinical Bio-Banking Applications, Point-of-Care Applications and Large-Scale Cell Processing and Biomanufacturing. Its Clinical Bio-Banking Applications include AXP Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, PXP-LAVARE System and PXP-1000 System. Its Large-Scale Cell Processing and Biomanufacturing includes X-Series Products for general laboratory use and CAR-TXpress Platform for Clinical Manufacturing. AXP Automated Cell Separation System is an automated, fully closed cell separation system.
More about the company